IL-35 (mouse):Fc (human) (rec.)

Catalog number: CHI-MF-11135-C005
Brand: Chimerigen Laboratories
Packing: 5 ug
Other sizes: 25 ug
Price: € 260.00
Expected delivery time: 7 days
Quantity:

Product specifications for - IL-35 (mouse):Fc (human) (rec.)

Overview: 
Product group: Proteins / Signaling Molecule
Category: Chemokines / cytokines
Species: Mouse
Source: CHO cells
Properties: 
Purity: >98% (SDS-PAGE)
Datasheet: Datasheet
  Research Use Only
UNSPSC: 41116127
Form supplied: Lyophilized from 0.2um-filtered solution in PBS.
Storage instructions: Store at -20°C
Scientific information: 
Scientific info: Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy. Recently, insufficient IL-35 levels were shown to play a pivotal role in the development of type 1 diabetes (T1D) and autoimmune diseases.
Swiss prot ID: NP_032377.1
Additional information: 
Synonyms: CHI-MF-11135-C005; Chimerigen Laboratories; Interleukin-35
Interleukin-35 administration counteracts established murine type 1 diabetes - possible involvement of regulatory T cells: K. Singh, et al.; Sci. Rep. 5, ID12633 (2015) Read more
Cytokine modulation by IL-35 in mice with allergic rhinitis: M. Yokota, et al.; Am. J. Rhinol. Allergy 29, 251 (2015) Read more
Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice: Z. Cai, et al.; Clin. Exp. Immunol. 181, 253 (2015) Read more
Intranasal administration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis: M. Suzuki, et al.; Allergol. Int. (Epub ahead of print) (2016) Read more